Corbus Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases. Its lead product candidate includes Resunab, a novel oral endocannabinoid-mimetic drug, which is in Phase 2 clinical trials for the treatment of cystic fibrosis, systemic sclerosis, and skin-predominant dermatomyositis diseases. The company is based in Norwood, Massachusetts.
Bear Thesis on Corbus Pharma Could Cause a Crash Landing for High-Flying Biotech Stock Source: https://www.thestreet.com/story/138...sh-landing-for-high-flying-biotech-stock.html
This might sound dumb, but think of today as a pull-back. +60% is nothing for data release this good. AF is attacking.
Analyst Upgrade/Downgrade Update Brokerage firm: JMP Securities Change: Coverage Reiterated/Price Target Changed Previous Rating: N/A Current Rating: Market outperform Previous Price Target: $9 Current Price Target: $20
There will be swings ahead but in the end you can't hold good stocks down when the companies are well-managed and have a good product.
A set back today for CRBP: Corbus Pharma Drug Shows No Clinical Benefit for Cystic Fibrosis Patients Corbus Pharmaceuticals (CRBP) waves a sea of hands in front of investors' eyes Thursday to obscure dismal results from another mid-stage study of its experimental anti-inflammatory drug anabasum. In this four-month study of cystic fibrosis patients, the Corbus drug failed to improve lung function compared to a placebo. Overall respiratory symptoms, measured by a cystic fibrosis patient questionnaire, also showed no difference between anabasum and placebo. These were the two most important, prospectively defined efficacy endpoints measured in the Corbus phase II study. Both came back zero. No benefit.
With RSI below 40, I'd wait. See if it goes down to $7, and if it can hold that. Coincidentally, a month ago they direct offered 3.8M shares at $7 too. edit source: https://www.thestreet.com/story/140...cal-benefit-for-cystic-fibrosis-patients.html
See if this 5.60 area holds Has just one drug, Anabasum, that they are testing in 4 indications (systematic sclerosis, cystic fibrosis, dermatomyositis, lupus). Seems risky to me, like they are just throwing it at a bunch of stuff and hoping one sticks. It's a medical cannabis drug.
